Proportion of patients eligible for adjuvant immunotherapy in nonmetastatic clear-cell renal cell carcinoma treated with radical or partial nephrectomy

Int J Urol. 2022 Oct;29(10):1235-1237. doi: 10.1111/iju.14952. Epub 2022 Jun 13.

Authors

Ryuma Tanaka^{1

2}, Shingo Hatakeyama³, Hikari Miura¹, Tomoko Hamaya^{1

2}, Takahiro Yoneyama⁴, Chikara Ohyama^{1

3

4}

Affiliations

¹ Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
² Department of Urology, Mutsu General Hospital, Mutsu, Japan.
³ Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
⁴ Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

PMID: 35697523
DOI: 10.1111/iju.14952

No abstract available

MeSH terms

Carcinoma, Renal Cell* / pathology
Carcinoma, Renal Cell* / surgery
Humans
Immunotherapy
Kidney Neoplasms* / pathology
Kidney Neoplasms* / surgery
Nephrectomy

Grants and funding